The liposomal daunorubicin plus tamoxifen: Improving the stability, uptake, and biodistribution of carriers

Journal of Liposome Research

Volumn 22, Issue 2, 2012, Pages 168-176

  Shao, Ming ^a,b   Sun, Shou Li ^a   Li, Ming Hui ^a   Li, Bao Xin ^a   Yu, Hui ^a   Shen, Zhi Ying ^a   Ren, Ya Chao ^a   Hao, Zhong Fei ^a   Chang, Nai Dan ^a   Peng, Hai Sheng ^a   Yang, Bao Feng ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; in vivo imaging; MCF 7 adr; Multidrug resistance

Indexed keywords

DAUNORUBICIN; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LEVEL; CELL STRAIN MCF 7; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG RETENTION; DRUG STABILITY; DRUG UPTAKE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DAUNORUBICIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG STABILITY; FEMALE; FLOW CYTOMETRY; HUMANS; LIPOSOMES; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROSCOPY, CONFOCAL; STRUCTURE-ACTIVITY RELATIONSHIP; TAMOXIFEN; TISSUE DISTRIBUTION;

EID: 84862087968     PISSN: 08982104     EISSN: 15322394     Source Type: Journal    
DOI: 10.3109/08982104.2012.668552     Document Type: Article

References (35)

1. Arozal, W, Watanabe, K, Veeraveedu, PT, Ma, M, Thandavarayan, RA, Sukumaran, V, et al. (2010). Protective effect of carvedilol on daunorubicin-induced cardiotoxicity and nephrotoxicity in rats. Toxicology 274: 18-26.
2. Aubel-Sadron, G., Londos-Gagliardi, D. (1984). Daunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review. Biochimie 66: 333-352. (Pubitemid 14058895)
3. Belvedere, G., Suarato, A., Geroni, C., Giuliani, F. C., D'Incalci, M. (1989). Comparison of intracellular drug retention, DNA damage, and cytotoxicity of derivatives of doxorubicin and daunorubicin in a human colon adenocarcinoma cell line (LoVo). Biochem Pharmacol 38: 3713-3721. (Pubitemid 19284019)
4. Berg, J. W., Hutter, R. V. (1995). Breast cancer. Cancer 75: 257-269.
5. Bodley, A, Liu, LF, Israel, M, Seshadri, R, Koseki, Y, Giuliani, FC, et al. (1989). DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA. Cancer Res 49: 5969-5978. (Pubitemid 19274156)
6. Ciesielska, E., Studzian, K., Wasowska, M., Oszczapowicz, I., Szmigiero, L. (2005). Cytotoxicity, cellular uptake, and DNA damage by daunorubicin and its new analogues with modified daunosamine moiety. Cell Biol Toxicol 21: 139-147. (Pubitemid 41666934)
7. Criscitiello, C., Fumagalli, D., Saini, K. S., Loi, S. (2010). Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection. Onco Targets Ther 4: 1-11.
8. Dano, K., Frederiksen, S., Hellung-Larsen, P. (1972). Inhibition of DNA and RNA synthesis by daunorubicin in sensitive and resistant Ehrlich ascites tumor cells in vitro. Cancer Res 32: 1307-1314.
9. Di Nicolantonio, F., Mercer, S. J., Knight, L. A., Gabriel, F. G., Whitehouse, P. A., Sharma, S., et al. (2005). Cancer cell adaptation to chemotherapy. BMC Cancer 5: 78.
10. Du, J, Lu, WL, Ying, X, Liu, Y, Du, P, Tian, W, et al. (2009). Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the bloodbrain barrier and survival of brain tumor-bearing animals. Mol Pharm 6: 905-917.
11. Guo, J., Zhou, J., Ying, X., Men, Y., Li, R. J., Zhang, Y., et al. (2010). Effects of stealth liposomal daunorubicin plus tamoxifen on the breast cancer and cancer stem cells. J Pharm Pharm Sci 13: 136-151.
12. Goldenberg, G. J., Froese, E. K. (1985). Antagonism of the cytocidal activity and uptake of melphalan by tamoxifen in human breast cancer cells in vitro. Biochem Pharmacol 34: 763-770. (Pubitemid 15107168)
13. Haran, G., Cohen, R., Bar, L. K., Barenholz, Y. (1993). Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1151: 201-215. (Pubitemid 23283973)
14. Hegedus, C, Ozvegy-Laczka, C, Apati, A, Magocsi, M, Nemet, K, Orfi, L, et al. (2009). Interaction of nilotinib, dasatinib, and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol 158: 1153-1164.
15. Hulhoven, R. (1978). Daunorubicin, daunorubicinol, and DNA plasma kinetics after I.V. administration of daunorubican-DNA complex in the rabbit. Biomedicine 29: 164-167. (Pubitemid 9012715)
16. Kayyali, R., Marriott, C., Wiseman, H. (1994). Tamoxifen decreases drug efflux from liposomes: relevance to its ability to reverse multidrug resistance in cancer cells? FEBS Lett 344: 221-224.
17. Lecompte, M. F., Laurent, G., Jaffrezou, J. P. (2002). Sphingomyelin content conditions insertion of daunorubicin within phosphatidylcholine monolayers. FEBS Lett 525: 141-144.
18. Leslie, K. K., Koil, C., Rayburn, W. F. (2005). Chemotherapeutic drugs in pregnancy. Obstet Gynecol Clin North Am 32: 627-640. (Pubitemid 41718955)
19. Liang, YG, Jorgensen, AG, Kaestel, CG, Wiencke, AK, Lui, GM, la Cour, MH, et al. (2000). Bcl-2, Bax, and c-Fos expression correlates to RPE cell apoptosis induced by UV-light and daunorubicin. Curr Eye Res 20: 25-34. (Pubitemid 30088804)
20. Licht, T., Fiebig, H. H., Bross, K. J., Herrmann, F., Berger, D. P., Shoemaker, R., et al. (1991). Induction of multiple-drug resistance during antineoplastic chemotherapy in vitro. Int J Cancer 49: 630-637.
21. Liscovitch, M., Lavie, Y. (2002). Cancer multidrug resistance: a review of recent drug discovery research. IDrugs 5: 349-355 (Pubitemid 38133051)
22. Mankhetkorn, S., Dubru, F., Hesschenbrouck, J., Fiallo, M., Garnier-Suillerot, A. (1996). Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells. Mol Pharmacol 49: 532-539.
23. Marbeuf-Gueye, C., Salerno, M., Quidu, P., Garnier-Suillerot, A. (2000). Inhibition of the P-glycoprotein-and multidrug resistance proteinmediated efflux of anthracyclines and calceinacetoxymethyl ester by PAK-104P. Eur J Pharmacol 391: 207-216. (Pubitemid 30154086)
24. Meriwether, W. D., Bachur, N. R. (1972). Inhibition of DNA and RNA metabolism by daunorubicin and adriamycin in L1210 mouse leukemia. Cancer Res 32: 1137-1142.
25. Pallarés-Trujillo, J., López-Soriano, F. J., Argilés, J. M. (2000). Lipids: akey role in multidrug resistance? (Review). Int J Oncol 16: 783-798.
26. Panasci, L., Jean-Claude, B. J., Vasilescu, D., Mustafa, A., Damian, S., Damian, Z., et al. (1996). Sensitization to doxorubicin resistance in breast cancer cell lines by tamoxifen and megestrol acetate. Biochem Pharmacol 52: 1097-1102. (Pubitemid 26338268)
27. Sadzuka, Y., Hatakeyama, H., Sonobe, T. (2010). Enhancement of doxorubicin concentration in the M5076 ovarian sarcoma cells by cucurbitacin E co-treatment. Int J Pharm 383: 186-191.
28. Sargent, J. M., Williamson, C. J., Maliepaard, M., Elgie, A. W., Scheper, R. J., Taylor, C. G. (2001). Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia. Br J Haematol 115: 257-262. (Pubitemid 34203486)
29. Shadle, S. E., Bammel, B. P., Cusack, B. J., Knighton, R. A., Olson, S. J., Mushlin, P. S., et al. (2000). Daunorubicin cardiotoxicity: evidence for the importance of the quinone moiety in a free-radicalindependent mechanism. Biochem Pharmacol 60: 1435-1444.
30. Tiwari, A. K., Sodani, K., Dai, C. L., Ashby, C. R. Jr., Chen, Z. S. (2011). Revisiting the ABCs of multidrug resistance in cancer chemotherapy. Curr Pharm Biotechnol 11: 570-594.
31. Turk, D., Szakacs, G. (2009). Relevance of multidrug resistance in the age of targeted therapy. Curr Opin Drug Discov Devel 12: 246-252.
32. Vara-Salazar Ede, L., Suárez-López, L., Angeles-Llerenas, A., Torres-Mejía, G., Lazcano-Ponce, E. (2011). Breast cancer mortality trends in Mexico, 1980-2009. Salud Publica Mex 53: 385-393.
33. Wiseman, H. (1994). Tamoxifen and estrogens as membrane antioxidants: comparison with cholesterol. Methods Enzymol 234: 590-602.
34. Ying, X., Wen, H., Yao, H. J., Zhang, Y., Tian, W., Zhang, L., et al. (2011). Pharmacokinetics and tissue distribution of dual-targeting daunorubicin liposomes in mice. Pharmacology 87: 105-114.
35. Zhigaltsev, I. V., Kaplun, A. P., Kucheryanu, V. G., Kryzhanovsky, G. N., Kolomeichuk, S. N., Shvets, V. I., et al. (2001). Liposomes containing dopamine entrapped in response to transmembrane ammonium sulfate gradient as carrier system for dopamine delivery into the brain of parkinsonian mice. J liposome Res 11: 55-71. (Pubitemid 32436255)